Anebulo Pharmaceuticals, Inc. (ANEB)

Anebulo Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Selling, General & Admin	5.36	4.92	4.76	6.18	3.87	1.34
Research & Development	3.74	4.3	3.55	5.6	2.96	2.27
Operating Expenses	9.1	9.22	8.31	11.78	6.83	3.61
Operating Income	-9.1	-9.22	-8.31	-11.78	-6.83	-3.61
Interest Expense	-0.3	-0.38	-0.15	-	-	-0.01
Interest & Investment Income	0.42	0.26	0.25	0.09	0.01	0
Other Non Operating Income (Expenses)	1	0.86	0.01	-0.04	-0	-26.63
Pretax Income	-7.98	-8.48	-8.2	-11.73	-6.83	-30.25
Net Income	-7.98	-8.48	-8.2	-11.73	-6.83	-30.25
Preferred Dividends & Other Adjustments	-	-	-	-	-	8.21
Net Income to Common	-7.98	-8.48	-8.2	-11.73	-6.83	-38.46
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	41	34	26	25	23	14
Shares Outstanding (Diluted)	41	34	26	25	23	14
Shares Change	55.97%	30.97%	2.98%	7.41%	71.49%	13.44%
EPS (Basic)	-0.19	-0.25	-0.32	-0.47	-0.29	-2.83
EPS (Diluted)	-0.19	-0.25	-0.32	-0.47	-0.29	-2.83
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
EBIT	-9.1	-9.22	-8.31	-11.78	-6.83	-3.61

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 17, 2026

Data Sources Report a data error